CoChat

The novel adipocytokine visfatin exerts direct cardioprotective effects

Open access
Lim, Shiang Y., Davidson, Sean M., Paramanathan, Ajeev J., Smith, Christopher C. T., Yellon, Derek M., Hausenloy, Derek J. · 2008 · Journal of Cellular and Molecular Medicine
Cited by 147

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Visfatin is an adipocytokine capable of mimicking the glucose‐lowering effects of insulin and activating the pro‐survival kinases phosphatidylinositol‐3‐OH kinase (PI3K)‐protein kinase B (Akt) and mitogen‐activated protein kinase kinase 1 and 2 (MEK1/2)‐extracellular signal‐regulated kinase 1 and 2 (Erk 1/2). Experimental studies have demonstrated that the activation of these kinases confers cardioprotection through the inhibition of the mitochondrial permeability transition pore (mPTP). Whether visfatin is capable of exerting direct cardioprotective effects through these mechanisms is unknown and is the subject of the current study. Anaesthetized C57BL/6 male mice were subjected to in situ 30 min. of regional myocardial ischaemia and 120 min. of reperfusion. The administration of an intravenous bolus of visfatin (5 × 10−6 μmol) at the time of myocardial reperfusion reduced the myocardial infarct size from 46.1 ± 4.1% in control hearts to 27.3 ± 4.0% (n≥ 6/group, P < 0.05), an effect that was blocked by the PI3K inhibitor, wortmannin, and the MEK1/2 inhibitor, U0126 (48.8 ± 5.5% and 45.9 ± 8.4%, respectively, versus 27.3 ± 4.0% with visfatin; n≥ 6/group, P < 0.05). In murine ventricular cardiomyocytes subjected to 30 min. of hypoxia followed by 30 min. of reoxygenation, visfatin (100 ng/ml), administered at the time of reoxygenation, reduced the cell death from 65.2 ± 4.6% in control to 49.2 ± 3.7%(n > 200 cells/group, P < 0.05), an effect that was abrogated by wortmannin and U0126 (68.1 ± 5.2% and 59.7 ± 6.2%, respectively; n > 200 cells/group, P > 0.05). Finally, the treatment of murine ventricular cardiomyocytes with visfatin (100 ng/ml) delayed the opening of the mPTP induced by oxidative stress from 81.2 ± 4 sec. in control to 120 ± 7 sec. (n > 20 cells/group, P < 0.05) in a PI3K‐ and MEK1/2‐dependent manner. We report that the adipocytokine, visfatin, is capable of reducing myocardial injury when administered at the time of myocardial reperfusion in both the in situ murine heart and the isolated murine cardiomyocytes. The mechanism appears to involve the PI3K and MEK1/2 pathways and the mPTP.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1582-4934.2008.00332.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 7 references

Cited by

See all 147

Metadata

Authors
Lim, S. Y., Davidson, S. M., Paramanathan, A. J., Smith, C. C. T., Yellon, D. M., & Hausenloy, D. J.
Venue
Journal of Cellular and Molecular Medicine
Publisher
Wiley
Published
2008-08
Volume
12
Issue
4
Pages
1395-1403
ISSN
  • 1582-1838 (ISSN-L)
  • 1582-4934
OpenAlex
W2028829631
Cited by
147
References
7
FWCI
8.64
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The novel adipocytokine visfatin exerts direct cardioprotective effects. https://app.cochat.ai/papers/10.1111/j.1582-4934.2008.00332.x
The paper
Lim, S. Y., Davidson, S. M., Paramanathan, A. J., Smith, C. C. T., Yellon, D. M., & Hausenloy, D. J. (2008). The novel adipocytokine visfatin exerts direct cardioprotective effects. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/j.1582-4934.2008.00332.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.